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Xanthoma disseminatum (XD) is an extremely rare cu-
taneous, normolipidemic, proliferative disorder of the 
Mononuclear Phagocyte System. It was first described 
by Von Gräfe and Virchow but recognized as a distinct 
entity by Montgomery & Osterberg in 1938 (1). Approx-
imately 140 cases are reported in the English literature. 
Clinically, XD is characterized by a symmetrical skin 
eruption of reddish papules or nodules, with predilec-
tion for the head, neck, flexural and intertriginous areas. 
These lesions, initially isolated, tend to slowly merge 
into large yellowish plaques, during years. The mean 
age at presentation is 30 years and male cases outnumber 
female ones by a ratio of 2:1. XD is generally thought to 
be a benign disorder with a chronic progressive course 
(2–4). Caputo et al. (5) recognized 3 clinical variants of 
XD: 1) a self-healing form; 2) a persistent form and 3) 
a progressive multi-system (MS) form. The report rate 
of this entity is becoming even lower now than in past 
years, perhaps due to its high diagnostic overlap with 
Erdheim-Chester Disease (ECD) (6, 7).
CASE REPORT
We hereby describe the case of a previously healthy 47-year-old 
Caucasian woman presented to our attention in January 2011, 
with a 2-year long history of cephalic xanthomas. Her lesions 
consisted of yellow periocular and perioral plaques extending to 
the zygomatic area as well as small yellow hard-elastic nodules 
growing next to the inner canthi (Fig. 1). Complete radiological, 
hematological (blood count, metabolic, renal and liver functions/
profiles) and endocrinological examinations all tested negative 
and failed to reveal any systemic involvement. Five years after 
our first diagnosis, she suffered of ischemic heart failure and 
therefore  underwent percutaneous revascularization to com-
plete normalization of cardiac function. During the following 
7 years, the lesions displayed a slow but progressive extension 
with symmetrical involvement of the whole face (Fig. 1). She 
never developed diabetes insipidus or any other signs of systemic 
involvement. Previous therapy (hydroxychloroquine and cyclo-
phosphamide) and surgeries (including CO
2
 laser therapy) led to 
constant recurrences and subsequent regrowth of lesions, together 
with surgery-related keloid scars, resulting in high mechanical, 
psychological and sociological impairment. Skin biopsy (Fig. 1) 
showed a polymorphic dense upper- and mid-dermal infiltration 
consisting of large histiocytes, admixed with few lymphocytes and 
neutrophils. Histiocytes were mostly characterized by large nuclei 
often with prominent nucleoli and an abundant pale cytoplasm. 
Foamy, Touton and Langhans cells were also present, focally in 
large numbers. There were no signs of epidermotropism. Immu-
nohistochemical profile of the histiocytes was positive for CD4, 
CD11c, CD14, CD68/PGM1, CD163, fXIIIa, vimentin, lysozyme, 
fascin but tested negative for CD1a, CD34 and CD207/langerin. 
Ki-67 stained 1–5 % of the cells. Altogether, clinical–pathological 
examination led to a non-conclusive diagnosis of xanthogranuloma 
vs xanthoma disseminatum. BRAFV600E analysis failed to reveal 
any alteration. Sixteen years after the first manifestation, the patient 
is alive and in a good clinical condition, although with chronic 
persistent evolution of the disfiguring lesions.
Informed consent was obtained in accordance with local ethical 
guidelines and with the Helsinki Declaration of 1975.
DISCUSSION
Histiocytoses have recently been reclassified in 5 dif-
ferent groups based on a combination of clinical, ra-
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Fig. 1. Clinical and histopathological 
features of the patient. The patient came 
to our attention with yellowish plaques 
limited to periocular and perioral regions 
(A, C). During the first 2 years of follow-
up the lesions slowly increased in volume 
and extended to columella (D) and after 
5 years they presented as thick tumor/
nodular lesions and confluent plaques 
extending to the forehead, zygoma, 
eyelids, outer nostrils and mentolabial sulci 
(B, E). Skin biopsy revealed a dense and 
polymorphic histiocytic infiltrate (F) made 
up of large cells with abundant and often 
foamy cytoplasm (G) and multinucleated 
giant cells of the Touton (H) and Langhans 



























































diographic, histopathological and molecular findings. 
XD belongs to the “xanthogranuloma-family” of the 
C(utaneous)-group, due to its prevalent skin involve-
ment and the polymorphic histiocytic infiltrate made of 
foamy cells, large histiocytes with abundant eosinophilic 
cytosol, and giant multinucleated cells of the Touton and 
Langhans-type (6–8).
Clinical presentation of XD is highly heterogeneous: 
the skin is always involved, but location and evolution of 
the lesions may be highly variable. Mucous membrane 
manifestations appear in up to 50% of cases. The growth 
of the lesions may cause severe mechanical impairment 
(e.g. mechanical blindness, respiratory obstruction or 
difficulty in defecation). Diabetes insipidus is commonly 
seen (40% of cases). Involvement of other organs (i.e. 
bones, kidneys, pancreas, uterus, lymph nodes, central 
nervous system) is described, although less frequent 
(2–4).
Differential diagnosis of XD is highly problematic, 
same as for other non-Langerhans-cell histiocytosis 
(NLCHs) (see Table SI1). Purely cutaneous (single-sys-
tem) XD cases generally involve multiple skin areas in-
cluding eyelids, neck, axillae, elbows, groin and perianal 
region and should be clinically differentiated from adult 
xanthogranuloma, based on the number, distribution and 
evolution of the lesions. Differential diagnosis may be 
more challenging for multi-system-xanthoma dissemina-
tum, as many clinical-pathological features coincide with 
the recently defined diagnostic criteria for ECD. For such 
reasons, those two rare histiocytoses have already been 
proposed to be a part of the same spectrum of entities, 
if not synonyms, as a matter of fact (9, 10). Our patient 
displays two very uncommon features for XD, namely 
the face-limited localization and the tumor-like lesions. 
In fact, the isolated cephalic involvement has been 
previously reported in only 3 cases (11). The limitation 
to head and neck region is seen in other NLCH but it is 
the predominant feature of benign cephalic histiocytosis 
(BCH), a pediatric histiocytosis presenting with a self-
limiting papular eruption. XD could be differentiated 
from BCH on the basis of epidemiological, clinical and 
histopathological findings. Even though the pathogenesis 
of such a disorder is practically unknown, one hypothesis 
could relate such circumscribed localization to some 
regional (dis-) immune factors (10). 
The development of nodular/tumor-like lesions, is 
otherwise seen in Progressive Nodular Histiocytosis 
(PNH), another rare C-histiocytosis characterized by 
a florid symmetrical proliferation of hundreds of large 
nodules/tumors all over the cutaneous surface. XD and 
PNH are generally indistinguishable from a histopatho-
logical point of view, although PNH may also display a 
spindle-shaped histiocyte morphology (12).
 The presence of BRAF mutations in a significant per-
centage of patients with histiocytosis and the consequent 
hyper-activation of the MAPK-pathway seems to play 
an important role in histiocytic disorders and they have 
been proposed as diagnostic markers for some entities 
(e.g. ECD) (13). To the best of our knowledge, the pre-
sent report is the only one that characterizes XD on a 
molecular level. Due to the limited amount of literature 
concerning the molecular landscape of XD, we consider 
it an important topic to be investigated. Even though the 
differential benefit of molecular analysis in histiocytoses 
has recently been denied, molecular characterization 
is important in order to gather information about the 
etiology and possibly prognostic stratification in such a 
rare disorder (13). 
The standard therapy strategy for XD is still undefi-
ned, although, several therapeutic strategies have been 
described (14). A review on XD patients, with long-term 
follow-up, recognized a subset of cases with therapy-
unrelated spontaneous partial or complete resolution 
of lesions (15). Beside these data, several other papers 
reported progression and/or death of XD patients even 
after aggressive chemotherapy regimens; consequently, 
the best therapeutic approach still needs to be weighed 
against the patient’s clinical severity (4, 11). 
In conclusion, we described a very unusual case of 
XD. Our patient’s features conform to the clinical he-
terogeneity of histiocytoses and show how differential 
diagnosis, prognostic stratification and therapeutic ap-
proach to NLCH may be incredibly troublesome. Future 
works should point out the clinical-pathological overlaps 
between NLCH and perhaps adopt a descriptive nomen-
clature (as for langerhans cell histiocytosis) allowing for 
an easier approach to therapeutic decisions.
The authors have no conflicts of interest to declare.
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Supplementary material to article by A. Bonometti et al. ”Disfiguring Nodular Cephalic Xanthoma Disseminatum: An Exceptional Variant of a 
Forgotten Entity”
Table SI. Summary of the main clinical-pathological features characterizing non-Langerhans-cell histiocytosis 







M:F 3:1 2.5:1 3:1 2/3:1 2:1
Age (years) 55–60 25–40 20–40 10–30 0–3
Diagnosis Clinical-pathological, radiological 
and molecular (?)
Clinical-pathological Clinical-pathological Clinical-pathological Clinical-pathological
Bone 95% (bilateral symmetric lesions 
of long bones).
Uncommon Uncommon None None
CNS/Diabetes insipidus 
(DI)
30% DI. Neurodegenerative CNS 
involvement described.
40% DI. CNS lesions, 
uncommon.
Uncommon None None
Skin Xanthelasma (33%), papules, 
plaques.
Xanthelasma, papules 
(confluent) plaques, nodules. 
Mucosal involvement
Single papules or 
nodules. Less often 
multiple papules
Hundreds of large 
nodules or tumor-like 
lesions all over the 
skin surface. Mucosal 
involvement
Several small papules 
distributed on head 
and neck region only
Histology Polymorphic histiocytic infiltrate with foamy cells (prevalent especially in late phase of 
disease), Touton giant cells and sometimes (PNH) spindled histiocytes. Background with 
mixed inflammatory infiltrate. 
Monomorphic non-foamy, non-epitheliomorphic 
histiocytic infiltrate admixed with few 
lymphocytes.
Electron microscopy Lipid vacuoles, myeloid bodies, highly developed endomembrane system, lysosomes, 
phagosomes.
Coated vesicles, comma-shaped bodies (20%)
Immunohistochemistry CD163+, CD68/PGM1+, CD68/KP1+, CD14+, CD4+, fXIIIa+, Vimentin+, S100+/–, CD1a–, CD207–.
Low Ki67 (5–10%)
BRAF 50% [13] n.d 7% [13] n.d. n.d.
Other mutations 45% [13] n.d 50–60% [13] n.d. n.d.
The table highlights the great overlap among these entities, which makes a correct diagnosis difficult to make.
